Exact Sciences' Q4 Revenues Flat, Loss Widens | GenomeWeb

NEW YORK (GenomeWeb News) – Exact Sciences today said that revenues in the fourth quarter were flat year over year, while its net loss widened.

The Madison, Wis.-based firm recorded $1.0 million in revenues for the three months ended Dec. 31, 2012, the same as a year ago and even with the average Wall Street estimate. All revenues came from licensing fees in the recently completed quarter, and the company had no product royalty fees, compared to $6,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.